Living Pharma, an immunotherapy developer, has been acquired just 18 months after being spun out from University of Maryland.
Living Pharma, a US-based immunotherapy developer based on research conducted at University of Maryland, has been acquired by biotech company Lentigen Technology for an undisclosed sum.
Living Pharma was spun out of Maryland’s School of Medicine 18 months ago, based on research by Eduardo Davila, associate professor of microbiology and immunology, and Koji Tamada, adjunct associate professor of otorhinolaryngology-head and neck surgery.
The spinout has developed immunotherapy that can be regulated, making it possible to switch off tumour-targeting T cells…
